RHUMADIC PLUS Tablet
ក្រុមហ៊ុនផលិតឱសថ:
SHAIMIL LABORATOIRES, India
- សារធាតុសកម្ម
- ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
- ផលរំខាន
- អន្តរប្រតិកម្ម
- ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
- ការប្រុងប្រយ័ត្នជាពិសេស
- សកម្មភាពឱសថ បរិយាយប័ណ្ណឱសថ
-
សារធាតុសកម្ម
Diclofenac sodium 50m, Paracetamol 500mg
-
ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
Indications & Dosage:
For treatment of pain or primary dysmenorrhea the recommended dosage is one tablet t.i.d.
For the relief of osteoarthritis the recommended dosage is one tablet b.i.d or t.i.d.
For the relief of rheumatoid arthritis the recommended dosage is one tablet b.i.d or t.i.d.
-
ផលរំខាន
In patients taking Diclofenac or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1%25-10% of patients are:
Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.
Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes and tinnitus.
Body as a whole: fever infection, sepsis
Cardiovascular system: congestive heart failure, hypertension, tachycardia, syncope
Digestive system: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatits, jaundice.
Hemic and lymphatic system: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia
Metabolic and nutritional: weight changes
Nervous system: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia, somnolence, tremors, malaise, nervousness, paresthesia, somnolence, tremors, vertigo
Respiratory system: asthma, dyspnea
Skin and appendages: alopecia, photosensitivity, sweating increased
Special senses: blurred vision urogenital system: cystitis, dysuria, hematuria, interstitial nephritis, orliguria/polyuria, proteinuria, renal failure.
-
អន្តរប្រតិកម្ម
Aspirin, Methotrexate, Cyclosporine, ACE inhibitors, Furosemide, Lithrium, Warfarin
Cardiovascular Thrombotic Events
Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal.
Hypertension
NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events.
Congestive Heart Failure and Edema
Fluid retension and edema have been observed in some patients taking NSAIDs.
Renal Effects
Caution should be used when initiating treatment with Diclofenac sodium in patients with considerablet dehydration.
Hepatic Effects
Elevations of one or more liver tests may occur during therapy with Diclofenac sodium.
-
ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
In late pregnancy, as with other NSAIDs, Cataflom should be avoided because it may cause premature closure of the ductus arteriosus.
-
ការប្រុងប្រយ័ត្នជាពិសេស
General
Anemia is sometimes seen in patients receiving NSAIDs, including diclofenac sodium.
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients.
Pre-existing Asthma: Patients with asthma may have aspirin sensitive asthma.
-
សកម្មភាពឱសថ
Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Diclofenac sodium, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
The main mechanism of action of paracetamol is considered to be the inhibition of cycloxygenase (COX), and recent findings suggest that it is highly selective for COX-2 Paracetamol is metabolised primarily in the liver, into non-toxic products.
*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។
ប្រភពព័ត៌មាន៖
- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp
- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp